Development of chemical approaches and technology for the design and preparation of glycoconjugate vaccines.

Glycoconjugate vaccines have shown efficiency to control infectious diseases and hold great promises in cancer immunotherapy. Nonetheless, there is an important need to identify novel immunostimulating carriers for carbohydrate antigens as well as to optimize the currently used protein carriers. This Mitacs project aims at developing versatile biochemical approaches and technology for the design and preparation of glycoconjugate vaccines. The interns will design vaccines based on protein nanoparticles and will engineer a known immunogenic protein carrier to enhance its efficacy to deliver glycoantigens. This project will lead to key advancements in the methodology of glycopeptide synthesis, glycoconjugation, and in the engineering of protein carriers for glycoantigens. Accordingly, this proposal is entirely aligned with the mission of Glycovax Pharma Inc, an emerging, fast-growing, clinical-stage Canadian biopharmaceutical company that aims at implementing molecular architectures to develop glycovaccines able to prevent cancers and infectious diseases.

Faculty Supervisor:

Steve Bourgault

Student:

Partner:

Glycovax

Discipline:

Life Sciences

Sector:

Biotechnology; Pharmaceuticals; Health and Related Sciences & Technology

University:

Université du Québec à Montréal

Program: